国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > News > Pharmaceutical News  > Pfizer's First-Quarter 2024 Financial statements

Pfizer's First-Quarter 2024 Financial statements

Pfizer published its Q1 2024 financial statements on May 1, 2024. GuideView1 MIN READMay 23, 2024


Solid Financial Results

Pfizer Inc. has announced its financial results for the first quarter of 2024, reporting revenues of $14.9 billion. The company's solid performance reflects continued growth in key products and significant progress in executing its 2024 priorities.

Revenue Decline and Growth

The first-quarter results saw a year-over-year operational revenue decrease of 19%, primarily due to the expected decline in revenues from Comirnaty and Paxlovid. However, excluding these contributions, Pfizer achieved an 11% operational revenue growth.

Earnings Per Share

Pfizer reported a first-quarter 2024 diluted EPS of $0.55 and an adjusted diluted EPS of $0.82. These figures include a favorable impact of $0.11 from a final revenue adjustment related to Paxlovid treatment courses returned by the U.S. government.

Cost Savings and Guidance

The company remains on track to deliver at least $4 billion in net cost savings by the end of 2024, as part of its previously announced cost realignment program. Pfizer reaffirmed its full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised its adjusted diluted EPS guidance to $2.15 to $2.35.

Outlook

Pfizer's first-quarter performance underscores its ability to drive growth in key areas despite challenges. The company's commitment to its financial targets and cost-saving initiatives positions it well for continued success throughout 2024.


Highlights

  • Pfizer reported first-quarter 2024 revenues of $14.9 billion.
  • There was a 19% year-over-year operational revenue decrease, mainly due to declining Comirnaty and Paxlovid revenues.
  • Excluding Comirnaty and Paxlovid, operational revenue grew by 11%.
  • Reported diluted EPS for the first quarter was $0.55, with an adjusted diluted EPS of $0.82.
  • The company is on track to achieve at least $4 billion in net cost savings by the end of 2024.
  • Pfizer reaffirmed its full-year 2024 revenue guidance of $58.5 to $61.5 billion and increased its adjusted diluted EPS guidance to $2.15 to $2.35.

Data Source: https://s28.q4cdn.com/781576035/files/doc_financials/2024/q1/Q1-2024-PFE-Earnings-Release.pdf


汉寿县| 龙陵县| 奉新县| 阜宁县| 霸州市| 嘉义县| 无棣县| 祁连县| 庐江县| 阳东县| 且末县| 汾阳市| 康保县| 日喀则市| 民和| 乳山市| 凤翔县| 博野县| 宝应县| 菏泽市| 新田县| 石林| 嫩江县| 平罗县| 黑龙江省| 日喀则市| 洪湖市| 措勤县| 江山市| 郁南县| 高台县| 界首市| 紫金县| 三穗县| 江华| 永清县| 天长市| 古丈县| 博白县| 凤凰县| 双牌县|